|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Jeltsch A: Beyond Watson and Crick: DNA
methylation and molecular enzymology of DNA methyltransferases.
Chembiochem. 3:274–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baylin SB, Esteller M, Rountree MR,
Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA
methylation, chromatin formation and gene expression in cancer. Hum
Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Knowles MA, Aveyard JS, Taylor CF, Harnden
P and Bass S: Mutation analysis of the 8p candidate tumour
suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer
Lett. 225:121–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bi Y, Zheng G, Mao HT and Zhuo WS:
Anti-oncogene RhoBTB2 and breast cancer. Int J Surg. 34:177–181.
2007.
|
|
6
|
Hamaguchi M, Meth JL, von Klitzing C, et
al: DBC2, a candidate for a tumor suppressor gene involved in
breast cancer. Proc Natl Acad Sci USA. 99:13647–13652. 2002.
View Article : Google Scholar
|
|
7
|
Chua YL, Ito Y, Pole JC, et al: The NRG1
gene is frequently silenced by methylation in breast cancers and is
a strong candidate for the 8p tumour suppressor gene. Oncogene.
28:4041–4052. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen L, Zhu Z, Sun X, et al:
Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast
carcinoma involves promoter methylation and associates with
metastasis. Breast Cancer Res Treat. 116:471–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Umbricht CB, Evron E, Gabrielson E,
Ferguson A, Marks J and Sukumar S: Hypermethylation of 14-3-3 sigma
(stratifin) is an early event in breast cancer. Oncogene.
20:3348–3353. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferguson AT, Evron E, Umbricht CB, et al:
High frequency of hypermethylation at the 14-3-3 sigma locus leads
to gene silencing in breast cancer. Proc Natl Acad Sci USA.
97:6049–6054. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi Y, Chen JY, Yang J, Li B, Chen ZH and
Xiao CG: DBC2 gene is silenced by promoter methylation in bladder
cancer. Urol Oncol. 26:465–469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu GP, Liao SG, Wang N and Wang YJ: The
association between DBC2 gene mutation and breast cancer in Chinese
population. Tumor Clin Res. 29:575–577. 2009.
|
|
13
|
Huang J, Zheng DL, Qin FS, et al: Genetic
and epigenetic silencing of SCARA5 may contribute to human
hepatocellular carcinoma by activating FAK signaling. J Clin
Invest. 120:223–241. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
15
|
Van Aelst L and D’Souza-Schorey C: Rho
GTPases and signaling networks. Genes Dev. 11:2295–2322.
1997.PubMed/NCBI
|
|
16
|
Nielsen R, Bustamante C, Clark AG, et al:
A scan for positively selected genes in the genomes of humans and
chimpanzees. PLoS Biol. 3:e1702005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stanelle J, Stiewe T, Theseling CC, Peter
M and Putzer BM: Gene expression changes in response to E2F1
activation. Nucleic Acids Res. 30:1859–1867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
D’Souza SJ, Vespa A, Murkherjee S, Maher
A, Pajak A and Dagnino L: E2F-1 is essential for normal epidermal
wound repair. J Biol Chem. 277:10626–10632. 2002.
|
|
19
|
Mao H, Qu X, Yang Y, Zuo W, Bi Y, Zhou C,
Yin H, Deng B, Sun J and Zhang L: A novel tumor suppressor gene
RhoBTB2 (RHOBTB2): Frequent loss of expression in sporadic breast
cancer. Mol Carcinog. 49:283–289. 2010.PubMed/NCBI
|
|
20
|
Jones PA and Takai D: The role of DNA
methylation in mammalian epigenetics. Science. 293:1068–1070. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singal R and Ginder GD: DNA methylation.
Blood. 93:4059–4070. 1999.PubMed/NCBI
|
|
22
|
Jones PA and Laird PW: Cancer-epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herman JG, Graff JR, Myohanen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: a novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan X, Inda M, Tunon T and Castresana J:
Improvement of the methylation specific PCR technical conditions
for the detection of p16 promoter hypermethylation in small amounts
of tumor DNA. Oncol Rep. 9:181–184. 2002.PubMed/NCBI
|
|
25
|
Belinsky SA, Nikula KJ, Palmisano WA, et
al: Aberrant methylation of p16(INK4a) is an early event in lung
cancer and a potential biomarker for early diagnosis. Proc Natl
Acad Sci USA. 95:11891–11896. 1998. View Article : Google Scholar : PubMed/NCBI
|
